 |
|
|
| |
Lack of Mericitabine Resistance Mutation NS5B S282T and Detection and Characterization of a Novel Mericitabine Double Resistance Mutation NS5B L159F+L320F in Patients Treated with Mericitabine Plus Peginterferon Alfa-2a (40KD)/Ribavirin Provides Further Evidence for the High Resistance Barrier to Mericitabine
|
| |
| |
Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
X. Tong,1 K. Piso,1 K. Haines,1 V. Baronas,1 L. Li,1 J-M. Yan,1 S. Le Pogam,1 R. Kulkarni,2 J. Thommes,2 K. Klumpp,1 I. N.jera1
1Hoffmann-La Roche Inc, Nutley, NJ, USA; 2Genentech, South San Francisco, CA, USA
|
| |
|
|
|
|
|
